|
pubmed:abstractText |
Although the need for adjuvant therapy in high-risk rectal cancer is widely accepted, controversies continue regarding timing, mode, and agents employed. The current recommended practice and its scientific basis are reviewed. Studies of induction therapy are discussed. Evidence of efficacy of new anticancer agents and modes of drug delivery are presented.
|
|
pubmed:affiliation |
Division of Colon and Rectal Surgery, Department of Surgery, Jefferson Medical College, Philadelphia, Pennsylvania, USA.
|
